Danuglipron Danuglipron is a small-molecule GLP-1 receptor agonist, formerly under development by Pfizer [1] that, in an oral formulation, was under investigation as a therapy for diabetes mellitus
Notably, the PNA model mimics a lean phenotype with subtle metabolic alterations and may phenocopy the human phenotype B of PCOS 45 , characterized by hyperandrogenism and oligo-anovulation, with cycle irregularities
Intracellular redox status controls spherogenicity, an in vitro cancer stem cell marker, in thyroid cancer cell lines
Vitamin Injections Even a minor imbalance in our bodies can cause weakness, fatigue, and weight gain
Diabetes Care 36 , 23462350 (2013)